Previous close | 362.10 |
Open | 363.40 |
Bid | 349.20 x N/A |
Ask | 385.90 x N/A |
Day's range | 361.60 - 368.70 |
52-week range | 224.50 - 385.70 |
Volume | |
Avg. volume | 25,878 |
Market cap | 20.267B |
Beta (5Y monthly) | 0.80 |
PE ratio (TTM) | N/A |
EPS (TTM) | -11.03 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
July 28, 2022 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that an extraordinary general meeting of shareholders will be held at 18:30 PM CEST on Thursday, September 8, 2022 at the offices of Freshfields Bruckhaus Deringer LLP, Strawinskylaan 10, 1077 XZ in Amsterdam, the Netherlands.The shareholders and all other persons with meeting rights are invit
$75 million in second quarter VYVGART® (efgartigimod alfa-fcab) global net product sales from U.S. and Japan commercial launch; approval in Europe on track for third quarter 2022Biologics License Application (BLA) for VYVGART accepted by China’s National Medical Products Administration (NMPA) as part of collaboration with Zai LabBLA for subcutaneous (SC) efgartigimod on track for filing by end of 2022Management to host conference call today at 2:30 pm CET (8:30 am ET) July 28, 2022 Breda, the Ne
July 21, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 28, 2022 at 2:30 pm CET (8:30 am ET) to discuss its half year 2022 financial results and provide a second quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx website at ar